Alberto M Pedroncelli

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

Mônica R. Gadelha, Marcello D. Bronstein, Thierry Brue et al. · The Lancet Diabetes & Endocrinology · 2014 · 395 citations

Medicine, Neurology, Pasireotide Versus

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Rosario Pivonello, Maria Fleseriu, John Newell‐Price et al. · The Lancet Diabetes & Endocrinology · 2020 · 198 citations

Linc 3, Withdrawal Phase, Medicine +6

Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?

Renato Cozzi, Roberto Attanasio, M Montini et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 187 citations · Full text

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

Mônica R. Gadelha, Marie Bex, Richard A. Feelders et al. · The Journal of Clinical Endocrinology & Metabolism · 2022 · 96 citations · Full text

Gender- and age-related differences in the endocrine parameters of acromegaly

Annamaria Colao, Giovanni Amato, Alberto M Pedroncelli et al. · Journal of Endocrinological Investigation · 2002 · 75 citations

Endocrine Mechanism, Neuroendocrinology, Gynecology +8